Local - Colorado

Add to Favorites | Subscribe | Share


  • (Press "esc" to clear)



breast cancer, breast cancer clinical trials, breast cancer stem cells, cancer stem cells, CK5, lynsey fettig, retinoic acid, retinoids, university of colorado cancer center

CU Cancer Center Study May Explain Failure of Retinoic Acid Trials Against Breast Cancer


University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining failure of retinoic acid trials against breast cancer and offers a possible strategy for their use.



cancer standard of care, national comprehensive cancer network, NCCN, Thomas Flaig, university of colorado cancer center

Thomas Flaig, MD, Named Chair of NCCN Bladder Cancer Panel

University of Colorado Cancer Center's Thomas Flaig, MD, has been named chair of the NCCN Clinical Practice Guidelines in Oncology Panel for Bladder Cancer, a group of 34 multidisciplinary bladder experts from NCCN Member Institutions that will influence the future direction of care for the disease.



cancer immunotherapy, gray zone lymphoma, Immunotherapy, lymphoma, lymphoma immunotherapy, manali kamdar, new england journal of medicine, university of colorado cancer center

NEJM Case Reports Show Promise of Cancer Immunotherapy to Treat Rare Lymphoma


Three case reports published in the New England Journal of Medicine demonstrate the promise of cancer immunotherapy in gray zone lymphoma, potentially paving the way for clinical trials utilizing this strategy in this and related conditions.



Michael Farrar Joins UCAR Leadership


Weather Service executive named UCAR senior vice president/chief operating officer



robert keith, york miller, University Of Colorado Cancer Center, denver veterans administration hospital, Lung Cancer, Cancer, Chemoprevention, prevent lung cancer, Iloprost

CU Cancer Center Chemoprevention Trial Hopes to Stop Lung Cancer Before It Starts


Ongoing clinical trial by University of Colorado Cancer Center investigators is evaluating the ability of an inhaled form of the pulmonary hypertension drug iloprost to prevent lung cancer.



heide ford, University Of Colorado Cancer Center, Breast Cancer, Cancer, Breast Cancer Metastasis, Cancer Stem Cells

Metastatic Breast Cancer Cells Use Hedgehog to ‘Evilize’ Docile Neighbors


University of Colorado Cancer Center study pinpoints promising link in the chain of hedgehog signaling that, when broken, could reduce the metastatic potential of breast cancer.



lia gore, University Of Colorado Cancer Center, childrens hospital colorado, ASCO 2017, ASCO Annual Meeting, CML, Chronic Myeloid Leukemia, Dasatinib

Dasatinib Excels in Worldwide Phase II Trial Against Pediatric CML


Worldwide phase II clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.



daniel pollyea, University Of Colorado Cancer Center, connect registry, ASCO 2017, Acute Myeloid Leukemia, Cancer

CONNECT Registry Shows Only 9 Percent Compliance with Genetic Testing Guidelines for Aml


Study presented at ASCO 2017 shows that only 9 percent of 259 evaluated AML patients received all seven of the NCCN-recommended genetic tests.



ross camidge, University Of Colorado Cancer Center, Lung Cancer, ALK positive lung cancer, Brigatinib, cancer clinical trial

Brigatinib First Drug to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib


FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer



University Of Colorado Cancer Center, Prostate Cancer, cancer clinical trial, prostate cancer clinical trial, Grape Seed Extract, alternative medicine

New Clinical Trial Framework Tests ‘Natural’ Cures for Cancer


A University of Colorado Cancer Center clinical trial is now recruiting prostate cancer patients who would otherwise be on a watch-and-wait protocol to test the ability of grape seed extract to slow the rise of prostate-specific antigen (PSA), a common marker of prostate cancer progression.

Chat now!